About NMD Pharma

NMD Pharma is a clinical-stage biotech company dedicated to enabling better lives through novel therapies designed to restore skeletal muscle health. We are advancing a first-in-class platform of small-molecule therapies that selectively target skeletal muscle to address rare neuromuscular diseases as well as broader age-related conditions with significant unmet medical need.

Building on more than 15 years of pioneering research in muscle physiology, NMD Pharma has established a world-leading muscle electrophysiology and translational research platform integrating deep biological insight, proprietary enabling technologies, small-molecule drug discovery capabilities, and robust in vivo pharmacology models. The platform is designed to translate fundamental muscle biology into clinically meaningful and sustained improvements in strength, function, and quality of life for patients.

Our lead development candidate, ignaseclant (formerly NMD670), is a first-in-class skeletal muscle-targeted therapy currently in clinical development for Charcot-Marie-Tooth disease (CMT), generalized myasthenia gravis (gMG), and spinal muscular atrophy (SMA). We are also advancing next-generation compounds and exploring additional biologic pathways that may support durable neuromuscular function across a range of disorders that result in a lack of normal muscle function.

Headquartered in Aarhus, Denmark, with operations in the United States, we have raised approximately $180 million from leading life science investors and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases.